Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - Long-term follow-up (LTFU) is essential for ensuring the ongoing effectiveness and safety of cell and gene therapies (CAGTs), with monitoring required for 5 to 15 years post-treatment to track delayed side effects and maintain treatment efficacy [4][7]. - The report emphasizes the need for a patient-centered, data-rich, and adaptable operational framework to address the complexities of LTFU studies, which differ significantly from traditional clinical trials [5][21]. - The future vision includes a more efficient and scalable LTFU process, integrating advanced data analytics and patient empowerment technologies, while fostering industry collaboration and data sharing [52][55]. Summary by Sections Challenges in Executing LTFU Studies - Maintaining patient engagement over long periods (5-15 years) is challenging due to potential patient dropouts and loss of interest from researchers [8][9]. - Data collection is complicated by the need to gather information across various healthcare systems and providers, leading to fragmented data [9][10]. - The geographical distribution of patients and their transitions to local healthcare providers complicate continuous data collection [10][11]. Strategies to Overcome LTFU Challenges - IQVIA employs a patient-friendly and data-efficient approach to address LTFU challenges, focusing on optimizing compliance, data quality, and patient retention while minimizing operational burdens [18]. - The design of LTFU studies must be tailored to each therapy, considering unique mechanisms of action and long-term success indicators [19][20]. - A patient-centered design approach is crucial, aligning research with the real-life experiences of patients post-treatment [20][21]. Future Vision for LTFU - The report envisions a seamless integration of LTFU into treatment development and post-market care, supported by collaborative frameworks and advanced data analytics [52][55]. - The potential for adaptive study designs that can evolve with changing scientific knowledge, regulatory frameworks, and technological tools is highlighted [47][48]. - The integration of LTFU with routine patient care is anticipated, reducing the distinction between research and healthcare [57][58]. Regulatory Leadership and Advocacy - IQVIA collaborates with regulatory bodies to shape industry standards for decentralized trial designs, registry integration, and data governance, promoting a patient-centered approach to LTFU [62].

Core Viewpoint - The article emphasizes the evolution of cancer treatment from merely achieving a five-year survival rate to ensuring quality long-term survival, focusing on both curing the disease and preserving the patient's quality of life [2]. Group 1: Information Asymmetry in Cancer Treatment - Cancer patients often face significant information asymmetry, complicating their treatment choices [3]. - The Guangzhou Taihe Cancer Hospital employs a multidisciplinary team (MDT) approach, requiring at least five specialties to discuss treatment options for each patient, ensuring comprehensive care [3][4]. - The hospital prioritizes the use of original research drugs, with over half of its medications being such, to enhance treatment effectiveness [3]. Group 2: Treatment Process and Quality - The hospital's meticulous approach to pathology analysis, such as creating multiple wax blocks from lymph nodes, aims to avoid missing small metastatic lesions, thereby improving treatment outcomes [5]. - Collaboration with renowned institutions like MD Anderson Cancer Center and Mayo Clinic enhances the hospital's treatment protocols and allows for international expert consultations for complex cases [6]. Group 3: Long-term Quality of Life Considerations - The focus on long-term quality of life is increasingly important, as many cancers are now manageable, making the preservation of organ function and minimizing treatment side effects critical [7][8]. - Proton therapy is highlighted as a method that targets tumors while protecting vital organs, addressing the long-term health risks associated with traditional treatments [8]. Group 4: Accessibility of Advanced Treatments - The high costs and complexity of implementing advanced treatments like proton therapy have historically limited patient access [9]. - Innovative payment solutions, such as the "Sui Xin Bao" health insurance in Guangzhou, are being developed to cover the costs of proton therapy, significantly improving accessibility for patients [9].

Financial Data and Key Metrics Changes - Order intake increased by 7% in Q4 2025, reflecting sustained improvement over the past year [5] - Comparable sales growth was 7% year-on-year, broad-based across all businesses and geographies [5] - Adjusted EBITDA margin improved by 160 basis points to 50.1% in Q4 2025, despite tariff impacts [5] - For the full year, adjusted EBITDA margin was 12.3%, exceeding the outlook [6][24] Business Line Data and Key Metrics Changes - Diagnosis and Treatment (D&T) saw comparable sales growth of 4% in Q4, with strong performance in Image-Guided Therapy [20] - Connected Care delivered 7% comparable sales growth in Q4, driven by double-digit growth in monitoring solutions [21] - Personal Health achieved 14% comparable sales growth in Q4, with all three businesses contributing [22] Market Data and Key Metrics Changes - North America remained the strongest growth driver, with sustained double-digit order intake growth [7][15] - In China, tender activity increased but faced challenges due to centralized procurement, leading to cautious near-term outlook [16][19] - Europe showed stable capital spending, while select international regions increased healthcare investments [17] Company Strategy and Development Direction - The company is focused on profitable growth acceleration, targeting mid-single-digit sales CAGR and mid-teens margins by 2028 [6][12] - Continued emphasis on innovation, particularly AI-enabled and patient-centric solutions, to drive future growth [10][12] - The company is enhancing patient impact and quality while simplifying operations and strengthening supply chain resilience [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong order intake momentum and improved execution [29] - The company expects comparable sales growth of 3%-4.5% in 2026, led by North America and international regions [19][30] - Management remains cautious about the near-term outlook for China but sees long-term growth potential [16][19] Other Important Information - The company generated EUR 1.2 billion in free cash flow in Q4 2025, despite a tougher comparison base [27] - Adjusting items decreased to EUR 179 million in Q4, reflecting a strong commitment to reducing these over time [26] - The company ended the quarter with approximately EUR 2.8 billion in cash and a leverage ratio improved to 1.7 times [28][29] Q&A Session Summary Question: Insights on gross margin improvement and order intake for D&T - Management confirmed gross margin improvement across Philips, driven by innovation and productivity, with continued margin expansion expected in 2026 despite tariff impacts [36][38] - Order intake for D&T was 5%, with strong contributions from Image-Guided Therapy and ultrasound innovations [39][40] Question: Clarification on 2026 guidance and margin buffers - Management acknowledged the dynamic environment and emphasized the importance of productivity and innovation for margin growth [43][44] Question: Performance of Precision Diagnosis and Q1 phasing - Management indicated that Precision Diagnosis returned to growth, with expectations for stronger performance in 2026 driven by new innovations [50][51] - Q1 is expected to start at the lower end of the growth range due to seasonality and tariff impacts [52][53] Question: Drivers behind strong personal health performance - Management highlighted market share gains and strong demand across geographies, with inventory levels now aligned with market averages [58][60] Question: Update on Section 232 investigation - Management stated that the investigation is ongoing, with potential measures that could replace tariffs but refrained from speculation on outcomes [61][62] Question: Outlook for China and margin dynamics - Management expects stable growth in China, with cautious optimism for personal health but uncertainty in health systems due to tender processes [67] - The strong margin in personal health was attributed to innovation, commercial execution, and productivity improvements [70][71]

Core Viewpoint - The establishment of the "Beijing Tumor Expert Workstation" at Shanghe County People's Hospital has significantly improved local cancer diagnosis and treatment capabilities, allowing patients to receive high-quality care close to home [3][4]. Group 1: Technical Advancements - The workstation has facilitated regular visits from top experts from institutions like the Chinese Academy of Medical Sciences Cancer Hospital and Peking University Cancer Hospital, leading to over 100 complex surgeries being performed since its inception in 2025 [4]. - The implementation of multidisciplinary team (MDT) consultations has enabled personalized treatment plans for complex cases, enhancing the local healthcare system's capabilities [4]. Group 2: Talent Development - The workstation emphasizes not only the infusion of expertise but also the cultivation of local medical talent through systematic training and mentorship from visiting experts [5]. - Local medical staff, such as Liu Chengliang, have improved their skills and service quality, providing comprehensive management for patients [5]. Group 3: Patient Benefits - The workstation has transformed the patient experience by combining advanced medical techniques with compassionate care, fostering trust and cooperation among patients [6][7]. - Patients receive not only standardized treatment but also emotional support and encouragement throughout their healthcare journey [7]. Group 4: Systematic Integration - The workstation serves as a foundation for the continuous development of oncology services at Shanghe County People's Hospital, integrating resources from various departments to create a comprehensive service system covering prevention, diagnosis, treatment, and rehabilitation [8]. - The hospital aims to enhance collaboration with Beijing expert teams and provide systematic training for young physicians, striving to make the workstation a regional hub for cancer prevention and treatment [8].

Group 1 - The core viewpoint of the article highlights the proactive measures taken by the Wending District Skin Disease Hospital in response to heavy snowfall, ensuring patient and staff safety during adverse weather conditions [1] - The hospital initiated an emergency response immediately after the snowfall, organizing all staff for a snow removal operation to create safe passageways for patients and their families [1] - Hospital leadership led by example, arriving early to coordinate the snow removal efforts, which involved multiple teams clearing key areas such as the outpatient hall entrance, parking lot, and accessible ramps [1] Group 2 - The snow removal operation was completed in about one hour, resulting in clear and safe pathways that effectively ensured the safety of patients, families, and healthcare personnel [1] - This initiative demonstrated the hospital staff's spirit of teamwork, practical responsibility, and commitment to serving the community, aligning with the core service philosophy of "patient-centered" care [1] - The hospital plans to continue monitoring weather changes and prepare for emergencies to maintain a safe, warm, and convenient treatment environment for patients [1]

Group 1 - The core viewpoint is that the Chinese healthcare industry is undergoing a profound transformation characterized by technological breakthroughs, innovative models, and social responsibility, culminating in a value evolution by 2025 [1] - The competition in the healthcare sector has expanded from mere technology or scale to a comprehensive comparison of innovation ecosystems, social responsibility, and sustainable development capabilities [1] - The 2025 Financial Innovation Economic Awards aim to recognize companies that embody a long-term perspective, support innovation, and safeguard life in the evolving healthcare landscape [1] Group 2 - A significant trend is that China is transitioning from being the largest medical application market to a source of cutting-edge innovation and solution incubation [2] - Notable events, such as GE Healthcare's global debut of the ExpertX quantum CT and significant R&D investments by companies like Hengrui Medicine and Innovent Biologics, indicate a shift from "fast following" to "source innovation" in Chinese healthcare [2] - Chinese companies are embedding "Chinese innovation" into the global R&D value chain through licensing and co-development models, while multinational companies are positioning China as a global R&D center [2] Group 3 - The boundaries of the healthcare industry are being redefined as the "Healthy China" strategy is implemented and public health awareness rises [3] - There is an accelerating integration of traditional healthcare and the broader health consumption market, with companies shifting focus from single products to comprehensive health solution ecosystems [4] - Companies like Yiling Pharmaceutical and Amway are transforming their business models to provide holistic health solutions, emphasizing a patient-centered approach [4] Group 4 - Leading companies are embedding social responsibility into their operational DNA, transforming philanthropy from an "add-on" to a "must-have" in their business strategies [4][5] - Initiatives such as Stryker's tree planting efforts and Tianjin's grassroots medical capacity building demonstrate a commitment to sustainable practices that create a positive impact on society [4] - The concept of "value co-existence" is highlighted, where corporate growth is closely linked to community health, environmental sustainability, and medical equity [5] Group 5 - The healthcare industry in 2025 will experience advancements driven by AI, precision medicine, and cell therapy, while also returning to the essence of healthcare, patient experience, and social responsibility [6] - The industry will continue to seek a balance between technological innovation and humanistic care, commercial expansion and social responsibility, as well as globalization and localization [6]

Core Viewpoint - The theme of this year's World Patient Safety Day is "Safe Care for Every Newborn and Child," emphasizing the importance of patient-centered research in the medical industry [1] Group 1: Patient-Centric Approach - The company prioritizes patient needs by integrating safety and effectiveness into clinical research processes, asking critical questions about treatment efficacy and trial safety [2] - The company has completed over 1,500 clinical studies across more than 20 indications, including solid tumors and cardiovascular diseases, with a focus on critical phases II and III [2] - AI technology has facilitated the recruitment of patients for over 1,200 projects, making patient-centered services more accessible [2] Group 2: Safety Measures - The company has developed a "6S Safety Defense Line," which encompasses standards and a commitment to scientific rigor and respect for life throughout the research process [2] - Safety is prioritized from study design to risk management, data monitoring, and result output, ensuring it remains the foundational principle [2] Group 3: Focus on Pediatric Medication - An online event was held to discuss the "6S Safety Defense Line" in pediatric drug development, highlighting insights and practical experiences from industry experts [3] - The complexity and importance of pediatric drug development were emphasized, including regulatory requirements and research strategies [5] - Ethical standards must be followed in pediatric drug development to maximize benefits and minimize risks, with a focus on dosage selection and child-specific endpoints [6] Group 4: Pharmacovigilance - Special attention is required for safety risks in pediatric clinical trials, including unique adverse reactions and pharmacokinetic differences in children [7] - Innovative monitoring technologies and long-term safety tracking strategies are being developed to ensure the safety and efficacy of pediatric medications [7] Group 5: Future Commitment - The company is committed to patient safety year-round, aiming to integrate technological innovation with professional services to create comprehensive solutions that meet clinical needs [8] - The mission to safeguard lives and ensure patient safety remains a collective effort within the organization [8]

Core Viewpoint - Johnson & Johnson aims to establish itself as a leader in the Chinese oncology market, focusing on innovation, collaboration, and patient-centered approaches to enhance its business in the next three years [1] Group 1: Innovation and R&D - Johnson & Johnson is currently the leading company in the blood cancer sector in China and plans to expand its innovation efforts into solid tumors [2] - The company has received approvals for 13 molecules and 26 indications in the oncology field over its 40 years in China, covering key cancers such as prostate cancer and multiple myeloma [2] - Recent breakthroughs in lung cancer treatments include a combination of dual antibodies and small molecule TKI inhibitors, significantly improving objective response rates and overall survival for advanced lung cancer patients [2][3] Group 2: Market Development and Collaboration - Johnson & Johnson's strategy involves deep collaboration with government, hospitals, and industry associations to enhance its market position in solid tumors [4] - The company is conducting real-world studies to gather data on drug efficacy and safety, particularly within the Chinese population, which will inform future R&D [4] - The company is optimizing its distribution channels by focusing on DTP pharmacy networks and training pharmacists to provide comprehensive patient care [4] Group 3: Patient-Centric Approach - Johnson & Johnson emphasizes the importance of making innovations meaningful for patients, ensuring accessibility and affordability of new treatments [7] - The company actively engages with regulatory bodies to expedite drug approval processes and participates in national health insurance negotiations to include its oncology drugs in the national reimbursement list [7] - Initiatives such as the "Tumor Patient Care Specialist" program and customized patient education packages aim to enhance patient experience and support long-term disease management [8]

Financial Data and Key Metrics Changes - Operating revenues surpassed $2,000,000,000 for the first time, reaching $2,020,000,000, which is a 14% increase in constant currency [34][13] - Net profit after tax was $377,200,000, reflecting a 30% increase in constant currency compared to the previous year [34][13] - Gross margin improved to 62.9%, an increase of 1.3% in constant currency [36] Business Line Data and Key Metrics Changes - Hospital business revenue was $1,280,000,000, up 16% in constant currency [34] - Home care business revenue reached $739,900,000, an 11% increase in constant currency [34] Market Data and Key Metrics Changes - The company’s products were used to treat 22 million patients in FY 2025, indicating strong market demand [30] - The manufacturing facility in China became fully operational, contributing to sales [31] Company Strategy and Development Direction - The company focuses on long-term planning, with a perspective extending beyond 15 years, guiding R&D and infrastructure investments [6][8] - Infrastructure investments include the construction of a fifth building at the East Tamaki campus and securing land for a second campus in New Zealand [8][7] - The company aims to double its revenue every five to six years sustainably [60] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of global geopolitics and tariffs but emphasized a long-term strategy to mitigate cost increases through continuous improvements [9][12] - The outlook for FY 2026 anticipates revenue between $2,150,000,000 and $2,250,000,000, with net profit after tax expected to be between $390,000,000 and $440,000,000 [56] Other Important Information - The company is committed to maintaining a prudent balance sheet while investing in R&D and global sales [14] - The board approved a 2% increase in dividends, totaling $0.0425 per share, representing a payout ratio of about 66% [13][14] Q&A Session Summary Question: Why hasn't the company conducted a major investor day like Xero? - The company complies with New Zealand regulations and believes its disclosures are adequate, thus not planning to adopt the Australian remuneration report [66] Question: What are the expectations for FY 2026 underlying profit? - Management referred to the outlook provided earlier, indicating a long-term growth trajectory despite fluctuations during the COVID period [68] Question: How many shareholders voted in favor of the CEO's reelection? - The number of votes will be disclosed at the end of the meeting, but the focus will be on the number of votes rather than individual shareholders [84]

Core Viewpoint - The article highlights the success of Yao Ying Medical, led by Dr. Shi Haoying, emphasizing the importance of high-quality medical services driven by doctors and focused on patient needs [1][6]. Group 1: Medical Core Philosophy - The core of Yao Ying Medical is "doctor-led" care, prioritizing effective and efficient solutions for patients, avoiding unnecessary treatments [3][4]. - The medical team consists of highly qualified professionals, with many having international experience, which enhances the institution's capability to handle complex cases [3][4]. Group 2: Patient-Centric Approach - High-quality medical care is defined as meeting the genuine health needs of patients, focusing on preventive measures and comprehensive health management [4][5]. - The "full-spectrum + specialty" team collaboration model allows for tailored solutions to patient health needs, integrating various medical disciplines [5]. Group 3: International Recognition and Innovation - Yao Ying Medical has gained global recognition, with international patients praising its services and expressing a desire for expansion [6][7]. - The institution actively incorporates cutting-edge medical practices and technologies, such as gene sequencing and AI-assisted health management, to enhance patient care [7]. Group 4: Empowerment of Medical Professionals - The establishment of Yao Ying Medical emphasizes the growth and empowerment of healthcare teams, fostering a collaborative environment focused on patient welfare [9][10]. - The institution attracts top medical talent, creating a culture of continuous improvement and teamwork [9][10]. Group 5: Future Aspirations - Dr. Shi Haoying envisions Yao Ying Medical becoming synonymous with high-quality healthcare in China over the next decade, aiming to reshape the industry with a patient-first philosophy [12].